MiMedx (MDXG) 10-K/A 22 Feb 17 2015 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Feb. 10, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	MIMEDX GROUP, INC.
Entity Central Index Key	1,376,339
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		107,810,490
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 1,135,614

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 28,486	$ 46,582
Short term investments	3,000	5,750
Accounts receivable, net	53,755	26,672
Inventory, net	7,460	5,133
Prepaid expenses and other current assets	3,609	1,540
Total current assets	96,310	85,677
Investments	0	3,250
Property and equipment, net of accumulated depreciation	9,475	5,447
Goodwill	4,040	4,040
Intangible assets, net of accumulated amortization	10,763	10,845
Deferred tax asset, net	14,838	0
Deferred financing costs and other assets	487	0
Total assets	135,913	109,259
Current liabilities:
Accounts payable	6,633	3,661
Accrued compensation	15,034	11,523
Accrued expenses	4,644	2,504
Other current liabilities	466	716
Total current liabilities	26,777	18,404
Other liabilities	1,148	1,526
Total liabilities	27,925	19,930
Commitments and contingencies
Stockholders' equity:
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding	0	0
Common stock; $0.001 par value; 150,000,000 shares authorized; 109,467,416 issued and 107,361,471 outstanding at December 31, 2015 and 108,776,247 issued and 107,789,611 outstanding at December 31, 2014	109	108
Additional paid-in capital	163,133	162,433
Treasury stock at cost: 2,105,945 shares at December 31, 2015 and 986,636 shares at December 31, 2014	(17,125)	(5,637)
Accumulated deficit	(38,129)	(67,575)
Total stockholders' equity	107,988	89,329
Total liabilities and stockholders' equity	$ 135,913	$ 109,259

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	109,467,416	108,776,247
Common stock, shares outstanding (in shares)	107,361,471	107,789,611
Treasury stock, shares (in shares)	2,105,945	986,636

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Net sales	$ 187,296	$ 118,223	$ 59,181
Cost of sales	20,202	12,665	9,328
Gross margin	167,094	105,558	49,853
Operating expenses:
Research and development expenses	8,413	7,050	4,843
Selling, general and administrative expenses	133,384	90,480	46,227
Impairment of intangible assets	0	0	368
Amortization of intangible assets	933	928	1,054
Operating income (loss)	24,364	7,100	(2,639)
Other income (expense), net
Amortization of debt discount	0	0	(1,328)
Interest expense, net	(86)	(48)	(45)
Income (loss) before income tax provision	24,278	7,052	(4,012)
Income tax provision	5,168	(832)	(100)
Net income (loss)	$ 29,446	$ 6,220	$ (4,112)
Net income (loss) per common share - basic (in dollars per share)	$ 0.28	$ 0.06	$ (0.04)
Net income (loss) per common share - diluted (in dollars per share)	$ 0.26	$ 0.05	$ (0.04)
Weighted average shares outstanding - basic (in shares)	105,929,205	105,793,008	96,285,504
Weighted average shares outstanding - diluted (in shares)	113,628,482	113,295,504	96,285,504

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in	Treasury Stock	Accumulated Deficit
Balance, beginning of period at Dec. 31, 2012	$ 20,007	$ 88	$ 89,627	$ (25)	$ (69,683)
Balance, beginning of period (in shares) at Dec. 31, 2012		88,423,169		50,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	6,010		6,010
Exercise of stock options	1,981	$ 2	1,979
Exercise of stock options (in shares)		1,958,674
Exercise of warrants	2,108	$ 2	2,106
Exercise of warrants (in shares)		1,844,352
Common stock issued for 5% convertible note	$ 5,272	$ 5	5,267
Common stock issued for 5% convertible note (in shares)	5,272,004	5,272,004
Common stock issued for earn - out liability	$ 5,792	$ 1	5,791
Common stock issued for earn-out liability (in shares)	1,174,915	1,174,915
Issuance of restricted stock	$ 0
Issuance of restricted stock (in shares)		2,500
Public offering of common stock, net of expenses	36,510	$ 6	36,504
Public offering of common stock, net of expenses (in shares)		5,750,000
Shares issued for services performed	0
Net income (loss)	(4,112)				(4,112)
Balance, end of period at Dec. 31, 2013	73,568	$ 104	147,284	$ (25)	(73,795)
Balance, end of period (in shares) at Dec. 31, 2013		104,425,614		50,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	11,453		11,453
Exercise of stock options	2,470	$ 2	2,468
Exercise of stock options (in shares)		1,653,690
Exercise of warrants	1,113	$ 1	1,112
Exercise of warrants (in shares)		1,242,416
Common stock issued for 5% convertible note	0
Common stock issued for earn - out liability	0
Issuance of restricted stock	0	$ 1	(1)
Issuance of restricted stock (in shares)		1,438,569
Shares issued for services performed	$ 117		117
Shares issued for services performed (in shares)	15,958	15,958
Stock repurchase	$ (5,612)			$ (5,612)
Stock repurchase (in shares)				936,636
Net income (loss)	6,220				6,220
Balance, end of period at Dec. 31, 2014	89,329	$ 108	162,433	$ (5,637)	(67,575)
Balance, end of period (in shares) at Dec. 31, 2014		108,776,247		986,636
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	16,896		16,896
Tax benefit of share-based compensation expense	7,757		7,757
Exercise of stock options	$ 4,629	$ 1	(9,792)	$ 14,420
Exercise of stock options (in shares)	2,220,881	647,656		(1,573,225)
Exercise of warrants	$ 46		(379)	$ 425
Exercise of warrants (in shares)				(42,400)
Common stock issued for 5% convertible note	0
Common stock issued for earn - out liability	0
Issuance of restricted stock	0		(14,547)	$ 14,547
Issuance of restricted stock (in shares)		34,250		(1,940,009)
Restricted stock shares canceled/forfeited	$ 0		652	$ (652)
Restricted stock shares canceled/forfeited (in shares)	69,949	(2,058)
Shares issued for services performed	$ 164		113	$ 51
Shares issued for services performed (in shares)	16,493	11,321		(5,172)
Stock repurchase	$ (40,279)			$ (40,279)
Stock repurchase (in shares)	4,610,000			4,610,166
Net income (loss)	$ 29,446				29,446
Balance, end of period at Dec. 31, 2015	$ 107,988	$ 109	$ 163,133	$ (17,125)	$ (38,129)
Balance, end of period (in shares) at Dec. 31, 2015		109,467,416		2,105,945

CONSOLIDATED STATEMENTS OF STO6

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)	Dec. 31, 2013	Dec. 31, 2011
5% Convertible Senior Secured Promissory Note
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Convertible note	5.00%	5.00%

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income (loss)	$ 29,446	$ 6,220	$ (4,112)
Adjustments to reconcile net income (loss) to net cash from operating activities:
Depreciation	1,799	1,197	637
Loss on fixed asset disposal	0	0	37
Amortization of intangible assets	933	928	1,054
Impairment of intangible assets	0	0	368
Amortization of debt discount and deferred financing costs	42	0	1,328
Share-based compensation	16,896	11,453	6,010
Change in deferred income taxes	(7,081)	0	0
Increase (decrease) in cash resulting from changes in:
Accounts receivable	(27,083)	(10,579)	(8,439)
Inventory	(2,327)	(1,252)	(858)
Prepaid expenses and other assets	(2,094)	(203)	(637)
Accounts payable	3,136	1,287	1,209
Accrued compensation	3,511	5,935	2,836
Accrued expenses	2,140	1,098	353
Accrued interest	0	0	(42)
Other liabilities	(511)	718	(28)
Net cash flows from operating activities	18,807	16,802	(284)
Cash flows from investing activities:
Purchases of equipment	(5,827)	(2,558)	(2,337)
Maturity (purchases) of fixed maturity securities	6,000	(9,000)	0
Patent application costs	(851)	(594)	(689)
Net cash flows from investing activities	(678)	(12,152)	(3,026)
Cash flows from financing activities:
Proceeds from exercise of stock options	4,629	2,470	1,981
Proceeds from exercise of warrants	46	1,113	2,108
Proceeds from public offering, net of expenses	0	0	36,602
Deferred financing costs	(504)	0	0
Stock repurchase	(40,279)	(5,612)	0
Principal payments of equipment leases	(117)	(117)	(57)
Net cash flows from financing activities	(36,225)	(2,146)	40,634
Net change in cash	(18,096)	2,504	37,324
Cash and cash equivalents, beginning of period	46,582	44,078	6,754
Cash and cash equivalents, end of period	$ 28,486	$ 46,582	$ 44,078

Nature of Business

Nature of Business	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	Nature of Business MiMedx Group, Inc. (“MiMedx,” "the Company,” “we,” or “us”) operates in one business segment, Regenerative Biomaterials, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The Company's biomaterial platform technologies include tissue technologies, AmnioFix and EpiFix, amniotic fluid derived allograft, OrthoFlo, and anticipated device technology CollaFix , which the Company has yet to commercialize. The Company is focused primarily on the United States but is actively exploring international expansion opportunities. The adoption of the technologies may vary depending on each country’s regulations, but the opportunities to help individuals in the different disease states remain similar and large.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported consolidated statements of operations during the reporting period. Actual results could differ from those estimates. Principles of Consolidation The accompanying financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries MiMedx, Inc., MiMedx Processing Services, LLC (formerly known as SpineMedica, LLC), and MiMedx Tissue Services, LLC (formerly known as Surgical Biologics, LLC). All significant inter-company balances and transactions have been eliminated. Segment Reporting ASC 280, “Segment Reporting” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company has determined it has one operating segment. Disaggregation of the Company’s operating results is impracticable, because the Company’s research and development activities and its assets overlap, and management reviews its business as a single operating segment. Thus, discrete financial information is not available for more than one operating segment . Market Concentrations and Credit Risk The Company places its cash and cash equivalents on deposit with financial institutions in the United States. In July 2010, the Federal Deposit Insurance Corporation (“FDIC”) increased coverage to $250,000 for substantially all depository accounts. As of December 31, 2015 and 2014, the Company had cash and cash equivalents of approximately $27,700,000 and $44,600,000 , respectively, in excess of the insured amounts. The Company’s principal market concentration of risk is related to its limited distribution channels. The Company's revenues include the distribution efforts of several independent companies as well as the Company's internal sales force. Significant revenues are derived from the Company's relationship with one of its distributors, AvKare, Inc. which sells our products to the Federal Government. For the years ended December 31, 2015, 2014 and 2013, AvKare revenue was approximately 24% , 34% , and 56% , of total revenue, respectively. Related receivables for the years ended December 31, 2015 and 2014 were approximately 26% , and 33% , of total accounts receivable, respectively. Cash and Cash Equivalents Cash and cash equivalents include cash and FDIC insured certificates of deposit held at various banks with an original maturity of three months or less. Accounts Receivable Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay. Investments Investments consist of FDIC insured certificates of deposit held at various banks and are classified as either Short term investments or Investments depending on their maturity date and are valued at cost, which approximates market value. Inventories Inventories are valued at the lower of cost or market, using the first–in, first-out (FIFO) method. Inventory is tracked through Raw Material, WIP, and Finished Good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes up to when the work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates. Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand. Goodwill and Purchased Intangible Assets Goodwill and purchased intangible assets with indefinite useful lives are not amortized but are tested for impairment at least annually. The Company reviews goodwill and purchased intangible assets with indefinite lives for impairment annually at the beginning of its fourth fiscal quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Potential impairment indicators include a significant change in the business climate, legal factors, operating performance indicators, competition, and the sale of disposition of a significant portion of the business. The Company first assesses certain qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the Company was less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the Company is less than its carrying amount, then the Company would perform a two-step quantitative impairment testing. In the first step, the Company compares the fair value of the Company to its carrying value. The Company determines the fair value utilizing the market approach. Under the market approach, the Company uses its market capitalization which is calculated by taking the Company’s share price times the number of outstanding shares. If the fair value of the Company exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the Company is less than the carrying value, the Company must perform the second step of the impairment test to measure the amount of impairment loss, if any. In the second step, the Company’s value is allocated to all of the assets and liabilities, including any unrecognized intangible assets, in a hypothetical analysis that calculates the implied fair value of goodwill in the same manner as if the Company was being acquired in a business combination. If the implied fair value of the reporting unit's goodwill is less than the carrying value, the difference is recorded as an impairment loss. Impairment of Intangible Assets with Finite Lives The Company reviews purchased intangible assets with finite lives for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable using a two-step impairment test. In step one, we determine the sum of the undiscounted future cash flows of the assets based on management's estimates and compare it to the carrying value of the assets. If the carrying amount is greater than the sum of the undiscounted cash flows, then the asset is impaired and step two is required. In step two, the impairment loss is calculated as the difference between the fair value of the assets and the carrying value of the assets. Impairment reviews are based on an estimated future cash flow approach that requires significant judgment with respect to future revenue and expense growth rates, selection of appropriate discount rate, asset groupings, and other assumptions and estimates. The Company uses estimates that are consistent with our business plans and a market participant view of the assets being evaluated. Actual results may differ from our estimates. During the fourth quarter of 2013, the Company chose to discontinue the HydroFix product line. This action resulted in an impairment charge of approximately $368,000 related to the Licenses for SaluMedica LLC, Spine Repair and Polyvinyl Alcohol Cryogel. This item is included in our Statement of Operations for the year ended December 31, 2013. An impairment charge of approximately $1,800,000 had previously been booked in 2012. Property and Equipment Property and equipment are recorded at cost and depreciated on a straight-line basis over their estimated useful lives, principally three to seven years. Leasehold improvements are depreciated on a straight-line basis over the lesser of the estimated useful lives or the life of the lease. The Company is party to various lease arrangements for its facility space and equipment. These arrangements include interest, scheduled rent increases and rent holidays which are included in the determination of minimum lease payments when assessing lease classification, and are included in rent expense on a straight line basis over the lease term. See Notes 7 and 16 for further information regarding capital leases, operating leases and rent expense. Patent Costs The Company incurs certain legal and related costs in connection with patent applications for tissue based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. The Company capitalized approximately $851,000 of patent costs during 2015, $594,000 of patent costs during 2014 and $689,000 of patent costs during 2013. Impairment of Long-lived Assets The Company evaluates the recoverability of its long-lived assets (property and equipment) whenever adverse events or changes in business climate indicate that the expected undiscounted future cash flows from the related assets may be less than previously anticipated. If the net book value of the related assets exceeds the expected undiscounted future cash flows of the assets, the carrying amount would be reduced to the present value of their expected future cash flows and an impairment loss would be recognized. During the fourth quarter of 2013, the Company chose to discontinue the HydroFix product line. This action resulted in a disposal loss of approximately $30,000 . This item is included in the Consolidated Statements of Operations for the year ended December 31, 2013, as Selling, General and Administrative expenses. Grant Income The Company received a Regional Economic Business Assistance ("REBA") grant in the amount of $250,000 from the State of Georgia to help the Company defray certain expenses and capital expenditures related to the Company's expansion of manufacturing activities in the State. In order to retain the grant monies the Company was required to add a certain number of full time positions and spend a certain amount on capital and operations expenditures by December 31, 2014. As of December 31, 2013, the Company had satisfied the grant requirements. Accordingly, the Company recorded the $250,000 as a reduction of Selling, General and Administrative expenses in the accompanying 2013 Consolidated Statements of Operations. Revenue Recognition The Company sells its products primarily through a combination of a direct sales force, independent stocking distributors and third - party representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships products directly to the end user, it recognizes revenue according to the shipping terms of the agreement provided all revenue recognition criteria have been met. A portion of the Company’s revenue is generated from inventory maintained at hospitals or with field representatives. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized. Research and Development Costs Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred. Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. Share-based Compensation The Company accounts for its share- based compensation plans in accordance with FASB ASC topic 718 “Compensation- Stock compensation”. FASB ASC 718 requires the measurement and recognition of compensation expense for all share-based awards made to employees and directors, including employee stock options, restricted stock and warrants. Under the provisions of FASB ASC 718, and U. S. Securities and Exchange Commission Staff Accounting Bulleting No. 107, share-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense on a straight line basis over the requisite service period of the entire award (generally the vesting period of the award). Fair Value of Financial Instruments The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature and type of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, short term investments, accounts payable and accrued expenses. The carrying cost of the Company’s investments also reflects their fair values due to the type of these investments and the fair value of capital leases approximates their carrying value based upon current rates available to the Company. Fair Value Measurements The Company records certain financial instruments at fair value, including: cash equivalents, short term investments and investments. The Company may make an irrevocable election to measure other financial instruments at fair value on an instrument-by-instrument basis; although as of December 31, 2015, the Company has not chosen to make any such elections. Fair value financial instruments are recorded in accordance with the fair value measurement framework. The Company also measures certain non-financial assets at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets, and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group, and accounting for business combinations. The Company uses the fair value measurement framework to value these assets and reports these fair values in the periods in which they are recorded or written down. The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels. These levels from highest to lowest priority are as follows: • Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities; • Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data. • Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available. The determination of fair value and the assessment of a measurement’s placement within the hierarchy require judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. The Company may also engage external advisors to assist it in determining fair value, as appropriate. Although the Company believes that the recorded fair value of its financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values. Recently Issued Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs"). In May 2014, the Financial Accounting Standards Board issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company is currently assessing the impact the adoption of ASU 2014-09 will have on its consolidated financial statements. In November 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company has adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify reporting with the release of the valuation allowance as disclosed in Note 13. Prior periods were not retrospectively adjusted. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements. All other ASUs issued and not yet effective for the year ended December 31, 2015, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.

Liquidity and Capital Resources

Liquidity and Capital Resources	12 Months Ended
	Dec. 31, 2015
Liquidity and Capital Resources [Abstract]
Liquidity and Capital Resources	Liquidity and Capital Resources Net Working Capital As of December 31, 2015, the Company had approximately $28,486,000 of cash and cash equivalents. The Company reported total current assets of approximately $96,310,000 and current liabilities of approximately $26,777,000 and had net working capital of approximately $69,533,000 . Overall Liquidity and Capital Resources The Company's largest cash requirement for the twelve months ended December 31, 2015 was cash for general working capital needs. In addition, the Company's other cash requirements included capital expenditures, and repurchases of the Company's common stock. The Company funded its cash requirements through its existing cash reserves, and its operating activities which generated approximately $18,807,000 during the period. The Company believes that its anticipated cash from operating and financing activities and existing cash and cash equivalents as well as its investments in FDIC insured certificates of deposit will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next year. In addition, on October 12, 2015, the Company entered into a new three -year $50 million senior secured revolving credit facility, which provides additional liquidity.

Cash Equivalents and Short Term

Cash Equivalents and Short Term Investments	12 Months Ended
	Dec. 31, 2015
Cash and Cash Equivalents [Abstract]
Cash Equivalent and Short Term Investments	Cash Equivalents and Short Term Investments Included in Cash and cash equivalents as of December 31, 2014, were approximately $1,250,000 of FDIC insured certificates of deposit held with various U.S. financial institutions. Short term investments at December 31, 2015 and 2014 consist of approximately $3,000,000 and $5,750,000 , respectively, of FDIC insured certificates of deposits held with various financial institutions. The cost of these instruments approximates their fair market value.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consisted of the following items as of December 31, 2015 and 2014 (in thousands): December 31, 2015 2014 Raw materials $ 602 $ 255 Work in process 3,850 3,419 Finished goods 3,405 1,986 Inventory, gross 7,857 5,660 Reserve for obsolescence (397 ) (527 ) Inventory, net $ 7,460 $ 5,133

Investments

Investments	12 Months Ended
	Dec. 31, 2015
Investments, All Other Investments [Abstract]
Investments	Investments Investments consisted of FDIC insured certificates of deposit with various U.S. financial institutions. The balance as of December 31, 2015 was zero and the balance as of December 31, 2014 was approximately $3,250,000 and the cost approximated fair market value. Maturities of these instruments range to May of 2016.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consist of the following as of December 31, 2015 and 2014 (in thousands): December 31, 2015 2014 Leasehold improvements $ 2,684 $ 2,559 Lab and clean room equipment 4,564 3,040 Furniture and equipment 4,577 2,398 Construction in Progress 2,629 949 Property and equipment, gross 14,454 8,946 Less accumulated depreciation (4,979 ) (3,499 ) Property and equipment, net $ 9,475 $ 5,447 Included in property and equipment is approximately $427,000 of capital leases. The corresponding liability of approximately $133,000 is included in other liabilities in the accompanying condensed consolidated balance sheet. Also included is approximately $1,000,000 in leasehold improvements paid for by the landlord of our main operating facility with a corresponding liability included in long term liabilities, which is amortized over the term of the lease. Depreciation expense for the years ended December 31, 2015, 2014, and 2013 was approximately $1,799,000 , $1,197,000 , and $637,000 , respectively.

Intangible Assets and Royalty A

Intangible Assets and Royalty Agreement	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Royalty Agreement	Intangible Assets and Royalty Agreement Intangible assets are summarized as follows (in thousands): December 31, 2015 2014 Weighted Cost Cost Licenses (a) (b) 10 years $ 1,009 $ 1,009 Patents & Know How (b) 17 years 8,001 7,891 Customer & Supplier Relationships (b) 14 years 3,761 3,761 Tradenames & Trademarks (b) indefinite 1,008 1,008 In Process Research & Development (b) n/a 25 25 Patents in Process (c) n/a 1,823 1,082 Total 15,627 14,776 Less Accumulated amortization (4,864 ) (3,931 ) Net $ 10,763 $ 10,845 (a) On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000 . Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2015, this license had a remaining net book value of approximately $110,000 . (b) On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000 , Patents & Know-How of $7,690,000 , Licenses of $13,000 , Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000 . During 2015 approximately $110,000 of additional costs associated with patents granted during the year were capitalized and included in Patents & Know- How subject to amortization. (c) Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization. Amortization expense for the years ended December 31, 2015, 2014, and 2013, was approximately $933,000 , $928,000 , and $1,054,000 , respectively. Expected future amortization of intangible assets as of December 31, 2015, is as follows (in thousands): Estimated Amortization Year ending December 31, Expense 2016 $ 936 2017 846 2018 836 2019 836 2020 836 Thereafter 5,465 $ 9,755

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt Senior Secured Promissory Notes From December 27 to December 31, 2011, the Company sold 5% Convertible Senior Secured Promissory Notes (the “Notes”) to individual accredited investors for aggregate proceeds of $5,000,000 . The aggregate proceeds included $500,000 of Notes sold to the Company’s Chairman of the Board and CEO. In total, the principal of the Notes were convertible into up to 5,000,000 shares of common stock of the Company (“Common Stock”) plus accrued but unpaid interest at $1.00 per share at any time upon the election of the holder of the note. In conjunction with the sale of the Notes, the Company incurred a placement fee of $32,800 and issued 42,400 common stock warrants to the placement agents at an exercise price of $1.09 per share. These warrants were exercised in November 2015. The fair value of the warrants was determined to be approximately $15,000 using the Black-Scholes-Merton valuation technique. The total direct costs of approximately $47,800 were recorded as deferred financing costs and were amortized over the term of the Notes using the effective interest method. Further, the placement agent warrants are classified in stockholders’ equity because they achieved all of the requisite conditions for equity classification in accordance with GAAP. During the months of January and February 2013, all holders of the Notes converted their interest in this obligation to shares of MiMedx common stock. The total amount of debt plus accrued interest that was exchanged was approximately $5,272,000 . In conjunction with this exchange, approximately 5,272,000 shares of the Company’s common stock were issued in full satisfaction of this obligation. Included in this total are 532,260 shares representing the CEO’s conversion of his Note. This also resulted in the acceleration of amortization of debt discount and total interest expense of approximately $1,328,000 during the year ended December 31, 2013. Credit Facility On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to $50 million . The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million , which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. Borrowings under the facility will bear interest at LIBOR plus 1.5% to 2.25% . Fees paid in connection with the initiation of the credit facility totaled approximately $500,000 . These deferred financing costs are being amortized to interest expense over the three -year life of the facility. The Credit Agreement contains customary representations, warranties, covenants, and events of default. As of December 31, 2015, there were no outstanding revolving loans under the credit facility.

Net Income (loss) Per Share

Net Income (loss) Per Share	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Net Income (loss) Per Share	Net Income (loss) Per Share Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period. Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, warrants and restricted stock using the treasury stock method. The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except per share data): Year Ended December 31, 2015 2014 2013 Net income (loss) $ 29,446 $ 6,220 $ (4,112 ) Denominator for basic earnings per share - weighted average shares 105,929,205 105,793,008 96,285,504 Effect of dilutive securities: Stock options, warrants, and restricted stock (a) 7,699,277 7,502,496 — Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities 113,628,482 113,295,504 96,285,504 Income (loss) per common share - basic 0.28 0.06 (0.04 ) Income (loss) per common share - diluted $ 0.26 $ 0.05 $ (0.04 ) (a) Securities that are included in the computation of the denominator above, utilizing the treasury stock method for the years ended December 31, 2015 and 2014 are as follows: Effect of dilutive securities: 2015 2014 Stock Options 7,121,774 7,035,728 Warrants 33,676 226,926 Restricted Stock Awards 543,827 239,842 7,699,277 7,502,496 Securities for the year ended December 31, 2013 were excluded from the computation of diluted earnings per share because they would have been anti-dilutive.

Common Stock Placements

Common Stock Placements	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Common Stock Placements	Common Stock Placements Public Offering of Common Stock In December of 2013, the Company completed a public offering (the "Offering”) of 5,750,000 shares of its common stock at $6.80 per share. Proceeds from the Offering, net of underwriting expenses were $36,704,000 . In addition, the Company incurred approximately $194,000 in various legal fees for services related to the Offering. Proceeds from the Offering were used for general corporate purposes, including, but not limited to, research, development and further commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures, working capital and future acquisitions of complementary businesses, technology or products.

Equity

Equity	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity	Equity Stock Incentive Plans The Company has three share-based compensation plans: the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “2006 Plan”), the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”) which provide for the granting of qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the 2006 Plan to make future grants. The number of assumed options under the Assumed 2005 Plan and Assumed 2007 Plan outstanding at December 31, 2015, totaled 70,000 . The maximum number of shares of common stock that can be issued under the 2006 Plan total 26,500,000 at December 31, 2015 . Activity with respect to the stock options is summarized as follows: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Outstanding at January 1, 2015 16,474,227 $ 3.43 Granted 75,100 $ 9.66 Exercised (2,220,881 ) $ 2.08 Unvested options forfeited (239,322 ) $ 6.66 Vested options expired (69,495 ) $ 2.61 Outstanding at December 31, 2015 14,019,629 $ 3.62 6.5 $ 80,740,577 Vested at December 31, 2015 10,951,694 $ 2.80 6.2 $ 71,955,234 Vested or expected to vest at December 31, 2015 (a) 13,917,122 $ 3.60 6.5 $ 80,496,150 (a) Includes forfeiture adjusted unvested shares. The intrinsic value of the options exercised during the years ended December 31, 2015, 2014 and 2013 were approximately $17,181,000 , $10,566,000 , and $8,864,000 , respectively. The intrinsic value of options vested during the years ended December 31, 2015, 2014 and 2013 were approximately $10,044,000 , $6,615,000 , and $3,351,000 , respectively. Following is a summary of stock options outstanding and exercisable at December 31, 2015: Options Outstanding Options Exercisable Range of Exercise Prices Number outstanding Weighted- Average Remaining Contractual Term (in years) Weighted- Average Exercise Price Number Exercisable Weighted- Average Exercise Price $0.50 - $0.76 441,429 3.4 $ 0.72 441,429 $ 0.72 $0.87 - $1.35 4,783,304 5.7 1.19 4,783,304 1.19 $1.40 - $2.45 1,641,928 5.1 1.93 1,641,928 1.93 $2.66 - $3.99 957,454 6.8 3.05 907,452 3.00 $4.19 - $6.38 3,552,323 7.4 5.35 2,229,386 5.32 $6.45- $9.78 2,527,525 8.1 7.29 914,703 7.18 $9.90 - $10.99 115,666 8.9 10.43 33,492 10.50 14,019,629 6.5 $ 3.62 10,951,694 $ 2.80 A summary of the status of the Company’s unvested stock options as of December 31, 2015 is presented below: Unvested Stock Options Number of Weighted- Unvested at January 1, 2015 7,193,577 $ 3.08 Granted 75,100 $ 5.15 Cancelled (239,322 ) $ 3.79 Vested (3,961,420 ) $ 2.53 Unvested at December 31, 2015 3,067,935 $ 3.81 Total unrecognized compensation expense at December 31, 2015 , was approximately $6,241,000 and will be charged to expense through March 2017. The fair value of the options granted was estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options. The term of employee options granted is derived using the “simplified method” which computes expected term as the midpoint between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company’s lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded. The term for non-employee options is generally based upon the contractual term of the option. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described. The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table: Year ended December 31, 2015 2014 2013 Expected volatility 54.35 - 58.14% 58.14 - 64.50% 61.41 - 64.77% Expected life (in years) 6 6 6 Expected dividend yield — — — Risk-free interest rate 1.51 - 1.68% 1.64 - 1.96% 0.85 - 1.88% The weighted-average grant date fair value for options granted during the years ended December 31, 2015 , 2014 and 2013 were approximately $5.15 , $4.18 and $3.08 , respectively. Restricted Stock Awards Following is summary information for restricted stock awards for the year ended December 31, 2015. Shares vest over a one to three year period. As of December 31, 2015, there was approximately $16,606,000 of total unrecognized stock-based compensation related to time-based, non-vested restricted stock. That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.1 years . Additionally, during the twelve months ended December 31, 2015, 5,172 shares of common stock valued at approximately $57,000 were issued under the 2006 Plan to a consultant in return for services performed. Number of Weighted-Average Grant Date Unvested at January 1, 2015 1,228,898 $ 7.16 Granted 1,974,259 $ 9.80 Vested (517,883 ) $ 6.90 Forfeited (72,007 ) $ 9.77 Unvested at December 31, 2015 2,613,267 $ 9.14 For the years ended December 31, 2015, 2014, and 2013 the Company recognized stock-based compensation as follows (in thousands): Year Ended December 31, 2015 2014 2013 Cost of sales $ 352 $ 322 $ 279 Research and development 790 660 417 Selling, general and administrative 15,754 10,471 5,314 $ 16,896 $ 11,453 $ 6,010 Warrants On November 18, 2015, 42,400 common stock warrants representing the balance remaining from those granted in connection with equity share purchases by investors as an additional incentive for providing long - term equity capital to the Company and as additional compensation to consultants and advisors were exercised at an exercise price of $1.09 . The warrants were granted at negotiated prices in connection with the equity share purchases and at the market price of the common stock in other instances. The warrants were issued for terms of five years . Treasury Stock On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2016. In December 2014, the Board increased the authorization to $20 million and further increased the authorization in 2015 to $60 million . The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time. For the year ended December 31, 2015, the Company purchased approximately 4,610,000 shares of its common stock for an aggregate purchase price of approximately $40,143,000 exclusive of commissions of approximately $136,000 . As of December 31, 2015, the Company had approximately $14,274,000 remaining under the repurchase program.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands): December 31, 2015 2014 Deferred tax assets and liabilities: Accruals and prepaids $ 4,606 $ 3,563 Intangible assets 146 619 Property and equipment (1,396 ) (770 ) R&D and other tax credits 3,293 2,086 Stock compensation 7,063 4,163 Charitable contributions — 1 Federal and state basis difference 145 114 Net operating loss 1,763 6,382 Net deferred tax assets $ 15,620 $ 16,158 Valuation allowance (782 ) (16,158 ) $ 14,838 $ — The reconciliation of the Federal statutory income tax rate of 34% to the effective rate is as follows: December 31, 2015 2014 Federal statutory rate 34.00 % 34.00 % State taxes, net of federal benefit 3.33 % 9.58 % Non deductible compensation 0.63 % 5.59 % Meals & entertainment 2.27 % 5.55 % Stock based compensation - ISO 6.39 % 21.73 % Other (4.58 )% (5.92 )% Valuation allowance (63.33 )% (58.73 )% (21.29 )% 11.80 % Current and deferred income tax expense (benefit) is as follows (in thousands): December 31, 2015 December 31, 2014 Current: Federal $ 8,452 $ — State 1,218 832 Total current 9,670 832 Deferred: Federal (13,070 ) — State (1,768 ) — Total deferred (14,838 ) — Total expense $ (5,168 ) $ 832 Income taxes are based on estimates of the annual effective tax rate and evaluations of possible future events and transactions and may be subject to subsequent refinement or revision. Certain items of income and expense are not reported in tax returns and financial statements in the same year. The tax effect of such temporary differences is reported as deferred income taxes. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. The Company establishes a valuation allowance for deferred tax assets for which realization is not likely. As of December 31, 2015, our deferred tax assets were primarily the result of accrued liabilities, equity compensation, and tax credit and net operating loss carryforwards. A valuation allowance of approximately $782,000 and $16,158,000 was recorded against our gross deferred tax asset balance as of December 31, 2015, and December 31, 2014, respectively. For the year ended December 31, 2015, we recorded a net valuation allowance release of $15,376,000 on the basis of management's reassessment of the amount of its deferred tax assets that are more likely than not to be realized. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December 31, 2015, in part because in the current year we achieved three years of cumulative pretax income in the U.S. federal tax jurisdiction, management determined that there is sufficient positive evidence to conclude that it is more likely than not that additional deferred taxes are realizable. It therefore reduced the valuation allowance accordingly. At December 31, 2015, and December 31, 2014, the Company had income tax net operating loss ("NOL") carryforwards for federal and state purposes of $579,000 and $27,552,000 , respectively. If not utilized, the federal and state tax loss carryforwards will expire between 2026 and 2031. The Company has recorded a deferred tax asset for both federal and state NOL carryforwards of approximately $197,000 and approximately $1,566,000 , respectively. A valuation allowance remains recorded against the deferred tax asset for certain federal net operating loss carryovers in the amount of $197,000 due to limitations provided by Internal Revenue Code Section 382 and certain state net operating loss carryovers in the amount of $585,000 not expected to be utilized prior to expiration. The Company's net operating losses and tax credits are subject to annual limitations due to ownership change limitations provided by Internal Revenue Code Section 382. The Company has performed an analysis and determined that the limitation exceeds the utilization of NOLs in the current year and does not anticipate much limitation going forward. As a result of certain realization requirements of ASC 718, Compensation - Stock Compensation, the table of deferred tax assets and liabilities shown above does not include certain deferred tax assets as of December 31, 2015, and December 31, 2014, that arose directly from (or the use of which was postponed by) tax deductions related to equity compensation that are greater than the compensation recognized for financial reporting. During 2015, deferred tax assets in the amount of $7,757,000 were realized resulting in an increase to equity in the same amount. The Company has approximately $1,661,000 of remaining deferred tax assets that will result in an increase to equity, if and when these deferred tax assets are ultimately realized. The Company uses ASC 740 ordering when determining when excess tax benefits have been realized. The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in thousands): December 31, 2015 December 31, 2014 Unrecognized tax benefits - January 1 $ — $ — Gross increases - tax positions in current period 170 — Unrecognized tax benefits - December 31 $ 170 $ — Included in the balance of unrecognized tax benefits as of December 31, 2015 and December 31, 2014, are $170,000 and $0 , respectively, of tax benefits that, if recognized, would affect the effective tax rate. Also included in the balance of unrecognized tax benefits as of December 31, 2015 and December 31, 2014, are $170,000 and $0 , respectively, of tax benefits that, if recognized, would result in adjustments to other tax accounts, primarily deferred taxes. This amount is recorded in Other Liabilities in the accompanying consolidated balance sheets. The Company recognizes interest accrued related to unrecognized tax benefits and penalties as income tax expense. Related to the unrecognized tax benefits noted above, the Company accrued no penalties or interest during 2015, and, in total, as of December 31, 2015 has not recognized any liabilities for penalties or interest. During 2014, we also did not accrue any penalties or interest and, in total, as of December 31, 2014, had not recognized any liability for penalties or interest. The Company is subject to taxation in the US and various state jurisdictions. As of December 31, 2015, the Company’s tax years for 2012, 2013, 2014 and 2015 are subject to examination by the tax authorities. As of December 31, 2015, the Company is generally no longer subject to US federal, state, or local examinations by tax authorities for years before 2012.

Supplemental Disclosure of Cash

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities	12 Months Ended
	Dec. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities	Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities Selected cash payments, receipts, and noncash activities are as follows (in thousands) : Years Ended December 31, 2015 2014 2013 Cash paid for interest $ 86 $ 48 $ 36 Income taxes paid 2,293 384 61 Purchases of equipment financed through capital leases — — 355 Retirement of fixed assets 319 — — Deferred financing costs 504 — 27 APIC related tax adjustments 7,757 — — Stock issuance in connection with Earn-Out Liability of 1,174,915 shares — — 5,792 Stock issuance in exchange for convertible debt of 5,272,004 shares — — 5,272 Stock issuance of 16,493 and 15,958 shares in exchange for services performed in 2015 and 2014, respectively 164 117 — Tenant improvement incentive — — 997 Legal fees paid for public offering — — 102 Legal fees related to public offering included in accounts payable — — 30 Legal fees related to public offering included in accrued expenses — — 62

401k Plan

401k Plan	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
401k Plan	401k Plan The Company has a 401(k) plan (the “Plan”) covering employees who have attained 21 years of age and have completed three months of service. Under the Plan, participants may defer up to 100% of their eligible wages to a maximum of $18,000 per year (annual limit for 2015). Employees age 50 or over in 2015 may make additional pre-tax contributions up to $6,000 above and beyond normal plan and legal limits. Annually, the Company may elect to match employee contributions up to 6% of the employee’s compensation. Additionally, the Company may elect to make a discretionary contribution to the Plan. The Company did not provide matching contributions for the years ended December 31, 2015, 2014 and 2013.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contractual Arrangements In addition to the capital leases noted under Property and Equipment above, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next five years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space and to various charitable organizations. The estimated annual payments are as follows (in thousands): Year ended December 31, 2016 $ 2,818 2017 2,340 2018 1,766 2019 1,763 2020 352 $ 9,039 Rent expense for the years ended December 31, 2015, 2014 and 2013, was approximately $1,317,000 , $1,130,000 and $1,000,000 , respectively and is allocated among cost of sales, research and development, and selling, general and administrative expenses. Letters of Credit As a condition of the leases for the Company's facilities we are obligated under standby letters of credit in the amount of approximately $235,000 . These obligations are reduced at various times over the lives of the leases. FDA Untitled Letter, Draft Guidance and Related Litigation FDA Untitled Letter and Draft Guidance On August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market those micronized products. Since the issuance of the Untitled Letter, the Company has been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act, but discussions are continuing. The Company continues to market its micronized products but is also pursuing the Biologics License Application (“BLA”) process for certain of its micronized products. On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to MiMedx 16 months earlier. The Company submitted comments asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA’s statutory authority, is inconsistent with existing HCT/P regulations and the FDA’s prior positions, and is internally inconsistent and scientifically unsound. On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance. The FDA has also indicated that it will hold a public hearing on on a date in 2016 to be determined to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The Company has requested, and has been granted an opportunity to speak at this hearing. If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with cGMP. Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions would require significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately 12% of the Company's revenues in 2015. Related Litigation Following the publication of the Untitled Letter from the FDA regarding the Company’s micronized products in September 2013, the trading price of the Company’s stock declined and several putative shareholder class action lawsuits were filed against the Company and certain of its executive officers asserting violations of the Securities Exchange Act of 1934. The cases were consolidated in the United States District Court for the Northern District of Georgia. On November 17, 2015, the parties entered into a stipulation of settlement to settle the consolidated case in its entirety. The stipulation of settlement was filed with the Court on November 18, 2015. On November 19, 2015, the Court preliminarily approved the settlement and has set the final settlement hearing for April 5, 2016. OIG Subpoena In the fourth quarter of 2014, the Company received a subpoena from the Office of Inspector General, U.S. Department of Health and Human Services, or OIG, in connection with a civil investigation into matters primarily related to the Company's sales and marketing activities. In March 2015, the Company received notice from the Department of Justice that it declined at that time to intervene in the qui tam action that gave rise to the issuance of the subpoena. The qui tam plaintiff had 120 days from the date of the Department of Justice’s notice to proceed with the case. The 120 day period passed without initiation of the lawsuit. The plaintiff, who is an executive at the Company’s competitor Organogenesis, Inc., voluntarily dismissed the lawsuit in July 2015. This dismissal was approved by the Court on October 6, 2015. Patent Litigation MiMedx continues to diligently enforce its intellectual property against several entities. Currently, there are three actions pending, as described below: The Liventa Action First, there is an action pending against several entities in the in the United States District Court for the Northern District of Georgia, i.e., “the Liventa Action”. On April 22, 2014, the Company filed a patent infringement lawsuit against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages. In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. The Liventa Action was filed in the United States District Court for the Northern District of Georgia. MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity. On June 30, 2014, fact discovery began and the parties have engaged in extensive fact discovery. MiMedx served Infringement Contentions on August 29, 2014, and Defendants served Invalidity Contentions and Responses to Infringement Contentions on September 29, 2014. After a protracted series of meet and confers, MiMedx required Defendants to supplement their invalidity contentions in view of parallel Inter Partes Review ("IPR")(see further discussion, infra) proceedings. MTF complied on June 26, 2015. In September 2015, the Defendants filed a renewed Motion to Stay in light of the Patent Trial and Appeal Board's ("PTAB") decisions to institute IPRs on the ’437 and ’687 Patents, seeking a partial stay of the litigation as to the ’437, ’687, and ’494 Patents (i.e., the ’437 Patent family). MiMedx opposed the Motion to Stay with respect to the ’494 Patent and once again successfully defeated Defendants’ motion to stay. Claim Construction proceedings began in October 2014. The parties submitted proposed constructions for key terms for the ’701, ’092, ’437, ’687, ’207, and ’494 Patents. Briefing was completed in March 2015. On December 22, 2015, a Markman Hearing was held before Special Master Sumner C. Rosenberg. Over thirty disputed claim terms were at issue. One week later, on December 30, 2015, the Special Master issued its Report and Recommendation. Except for one term, the Special Master’s Report essentially adopted MiMedx’s proposed constructions. The parties are awaiting a final Court decision pending their respective objections. The Bone Bank Action On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. The Bone Bank Action is in an advanced stage. The parties have (i) substantially completed document production; (ii) taken several fact depositions (both party and non-party); and (iii) completed claim construction briefing. The Markman hearing in this case was held on October 2, 2015. Except for one term, the Court adopted MiMedx’s proposed construction of the disputed terms. The parties have submitted a proposed scheduling order to the Court and are awaiting the Court’s order in this regard. Meanwhile, the parties continue with fact discovery in view of recent depositions. The NuTech Action Finally, on March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers. On April 17, 2015, NuTech filed a motion to dismiss the case purportedly for lack of patentable subject matter, which the Company opposed. NuTech also filed a motion to stay the case pending disposition of the motion to dismiss, which MiMedx also opposed, and on which the Court declined to rule. Hearing on the motion to dismiss occurred on August 20, 2015. On November 24, 2015, the court ruled on NuTech’s Motion to Dismiss, granting in part, and denying in part. MiMedx still has claims against NuTech for infringement of the ‘494 and ‘687 patents, as well as violations of the Lanham Act; these claims shall proceed. On December 30, 2015, the parties submitted a Joint Rule 26(f) Report of Parties’ Planning Meeting and Proposed Case Management Order to the Court. In the Report, the parties requested that the Court stay the proceedings with respect to the ’687 patent pending the completion of the inter partes review on that patent. On January 8, 2016, MiMedx served its infringement contentions. Discovery has recently begun. Pending IPRs In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases have challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review (or "IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action have challenged the validity of the C ompany's 8,597,687 and 8,709,494 patents (the "'687" and "'494" patents, respectively); while the defendants in the Liventa Action have challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively). On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied defendants' request for institution of an IPR with respect to the '494 patent on all seven challenged grounds. On August 18, 2015, the PTAB also denied defendants' request for institution of an IPR with respect to the '701 patent on all six challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable. On July 10, 2015 the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only two of the five challenged grounds. The PTAB also adopted MiMedx's construction of the claims which will govern the Board's review of the '687 patent. On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on one of the seven challenged grounds. Briefing and expert discovery is ongoing. Following the PTAB decisions, the defendants in the Bone Bank Action moved to stay the district court litigation, despite the Court's previous denial of such a stay, pending the outcome of the '687 patent inter partes review. The parties agreed to stay the case with respect to the '687 patent only and the Court denied Bone Bank's motion to stay the litigation with respect to the '494 patent. The Company has also successfully defeated an attempt by defendants in the Liventa Action to stay that litigation -- also pending the outcome of the IPR of the patents at issue in that case.

Quarterly Financial Data (Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (Unaudited)	Quarterly Financial Data (Unaudited) (in thousands except per share data) First Quarter Second Quarter Third Quarter Fourth Quarter NET SALES 2015 $ 40,767 $ 45,679 $ 49,015 $ 51,835 2014 19,559 25,573 33,518 39,573 2013 11,556 13,515 16,116 17,994 GROSS MARGIN 2015 $ 35,619 $ 40,590 $ 44,036 $ 46,849 2014 16,582 22,833 30,170 35,973 2013 9,651 11,316 14,002 14,883 NET INCOME (LOSS) 2015 $ 4,087 $ 5,430 $ 6,551 $ 13,378 2014 (922 ) (390 ) 3,700 3,832 2013 (1,620 ) (757 ) (307 ) (1,427 ) NET INCOME (LOSS) 2015 $ 0.04 $ 0.05 $ 0.06 $ 0.13 2014 (0.01 ) — 0.03 0.04 2013 (0.02 ) (0.01 ) — (0.01 ) NET INCOME (LOSS) 2015 $ 0.04 $ 0.05 $ 0.06 $ 0.11 2014 (0.01 ) — 0.03 0.03 2013 (0.02 ) (0.01 ) — (0.01 )

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics, a provider of human tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare industry. The acquisition of Stability was effected by the merger of Stability Inc. into a newly created wholly owned subsidiary of the Company. The new subsidiary was the surviving company in the merger and was subsequently renamed Stability Biologics, LLC ("Stability"). The Company paid $10 million at the closing, comprised of 60% cash and 40% in shares of common stock of MiMedx Group, Inc., assumed approximately $800,000 in debt, and eliminated a $2.4 million receivable related to Company products sold to Stability prior to the acquisition . The Company will also pay future contingent consideration through a two -year earn out arrangement based on the 2016 and 2017 performance of Stability's business. The Company expects the earn out will be the larger portion of the overall consideration for the transaction. The earn out will also be paid in the form of 60% cash and 40% in shares of stock of MiMedx Group, Inc.

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	Schedule II Valuation and Qualifying Accounts MIMEDX GROUP, INC. AND SUBSIDIARIES SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS Years ended December 31, 2015, 2014 and 2013 (in thousands) Balance at Additions charged to Expense or Revenue Deductions Balance at For the Year ended December 31, 2015 Allowance for doubtful accounts $ 1,750 $ 1,698 $ (178 ) $ 3,270 Allowance for product returns 841 3,257 (2,836 ) 1,262 Allowance for obsolescence 527 540 (670 ) 397 For the Year ended December 31, 2014 Allowance for doubtful accounts $ 407 $ 1,357 $ (14 ) $ 1,750 Allowance for product returns 215 2,215 (1,589 ) 841 Allowance for obsolescence 322 405 (200 ) 527 For the Year ended December 31, 2013 Allowance for doubtful accounts $ 49 $ 391 $ (33 ) $ 407 Allowance for product returns 89 917 (791 ) 215 Allowance for obsolescence 159 213 (50 ) 322

Significant Accounting Polici27

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported consolidated statements of operations during the reporting period. Actual results could differ from those estimates.
Principles of Consolidation	Principles of Consolidation The accompanying financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries MiMedx, Inc., MiMedx Processing Services, LLC (formerly known as SpineMedica, LLC), and MiMedx Tissue Services, LLC (formerly known as Surgical Biologics, LLC). All significant inter-company balances and transactions have been eliminated.
Segment Reporting	Segment Reporting ASC 280, “Segment Reporting” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company has determined it has one operating segment. Disaggregation of the Company’s operating results is impracticable, because the Company’s research and development activities and its assets overlap, and management reviews its business as a single operating segment. Thus, discrete financial information is not available for more than one operating segment .
Market Concentrations and Credit Risk	Market Concentrations and Credit Risk The Company places its cash and cash equivalents on deposit with financial institutions in the United States. In July 2010, the Federal Deposit Insurance Corporation (“FDIC”) increased coverage to $250,000 for substantially all depository accounts. As of December 31, 2015 and 2014, the Company had cash and cash equivalents of approximately $27,700,000 and $44,600,000 , respectively, in excess of the insured amounts. The Company’s principal market concentration of risk is related to its limited distribution channels. The Company's revenues include the distribution efforts of several independent companies as well as the Company's internal sales force. Significant revenues are derived from the Company's relationship with one of its distributors, AvKare, Inc. which sells our products to the Federal Government.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash and FDIC insured certificates of deposit held at various banks with an original maturity of three months or less.
Accounts Receivable	Accounts Receivable Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.
Investments	Investments Investments consist of FDIC insured certificates of deposit held at various banks and are classified as either Short term investments or Investments depending on their maturity date and are valued at cost, which approximates market value.
Inventories	Inventories Inventories are valued at the lower of cost or market, using the first–in, first-out (FIFO) method. Inventory is tracked through Raw Material, WIP, and Finished Good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes up to when the work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates. Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.
Goodwill and Purchased Intangible Assets	Goodwill and Purchased Intangible Assets Goodwill and purchased intangible assets with indefinite useful lives are not amortized but are tested for impairment at least annually. The Company reviews goodwill and purchased intangible assets with indefinite lives for impairment annually at the beginning of its fourth fiscal quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Potential impairment indicators include a significant change in the business climate, legal factors, operating performance indicators, competition, and the sale of disposition of a significant portion of the business. The Company first assesses certain qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the Company was less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the Company is less than its carrying amount, then the Company would perform a two-step quantitative impairment testing. In the first step, the Company compares the fair value of the Company to its carrying value. The Company determines the fair value utilizing the market approach. Under the market approach, the Company uses its market capitalization which is calculated by taking the Company’s share price times the number of outstanding shares. If the fair value of the Company exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the Company is less than the carrying value, the Company must perform the second step of the impairment test to measure the amount of impairment loss, if any. In the second step, the Company’s value is allocated to all of the assets and liabilities, including any unrecognized intangible assets, in a hypothetical analysis that calculates the implied fair value of goodwill in the same manner as if the Company was being acquired in a business combination. If the implied fair value of the reporting unit's goodwill is less than the carrying value, the difference is recorded as an impairment loss.
Impairment of Intangible Assets with Finite Lives	Impairment of Intangible Assets with Finite Lives The Company reviews purchased intangible assets with finite lives for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable using a two-step impairment test. In step one, we determine the sum of the undiscounted future cash flows of the assets based on management's estimates and compare it to the carrying value of the assets. If the carrying amount is greater than the sum of the undiscounted cash flows, then the asset is impaired and step two is required. In step two, the impairment loss is calculated as the difference between the fair value of the assets and the carrying value of the assets. Impairment reviews are based on an estimated future cash flow approach that requires significant judgment with respect to future revenue and expense growth rates, selection of appropriate discount rate, asset groupings, and other assumptions and estimates. The Company uses estimates that are consistent with our business plans and a market participant view of the assets being evaluated. Actual results may differ from our estimates.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost and depreciated on a straight-line basis over their estimated useful lives, principally three to seven years. Leasehold improvements are depreciated on a straight-line basis over the lesser of the estimated useful lives or the life of the lease. The Company is party to various lease arrangements for its facility space and equipment. These arrangements include interest, scheduled rent increases and rent holidays which are included in the determination of minimum lease payments when assessing lease classification, and are included in rent expense on a straight line basis over the lease term.
Patent Costs	Patent Costs The Company incurs certain legal and related costs in connection with patent applications for tissue based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company.
Impairment of Long-lived Assets	Impairment of Long-lived Assets The Company evaluates the recoverability of its long-lived assets (property and equipment) whenever adverse events or changes in business climate indicate that the expected undiscounted future cash flows from the related assets may be less than previously anticipated. If the net book value of the related assets exceeds the expected undiscounted future cash flows of the assets, the carrying amount would be reduced to the present value of their expected future cash flows and an impairment loss would be recognized.
Grant Income	Grant Income The Company received a Regional Economic Business Assistance ("REBA") grant in the amount of $250,000 from the State of Georgia to help the Company defray certain expenses and capital expenditures related to the Company's expansion of manufacturing activities in the State. In order to retain the grant monies the Company was required to add a certain number of full time positions and spend a certain amount on capital and operations expenditures by December 31, 2014. As of December 31, 2013, the Company had satisfied the grant requirements.
Revenue Recognition	Revenue Recognition The Company sells its products primarily through a combination of a direct sales force, independent stocking distributors and third - party representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships products directly to the end user, it recognizes revenue according to the shipping terms of the agreement provided all revenue recognition criteria have been met. A portion of the Company’s revenue is generated from inventory maintained at hospitals or with field representatives. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.
Research and Development Costs	Research and Development Costs Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.
Share-based Compensation	Share-based Compensation The Company accounts for its share- based compensation plans in accordance with FASB ASC topic 718 “Compensation- Stock compensation”. FASB ASC 718 requires the measurement and recognition of compensation expense for all share-based awards made to employees and directors, including employee stock options, restricted stock and warrants. Under the provisions of FASB ASC 718, and U. S. Securities and Exchange Commission Staff Accounting Bulleting No. 107, share-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense on a straight line basis over the requisite service period of the entire award (generally the vesting period of the award).
Fair Value of Financial Instruments	Fair Value of Financial Instruments The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature and type of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, short term investments, accounts payable and accrued expenses. The carrying cost of the Company’s investments also reflects their fair values due to the type of these investments and the fair value of capital leases approximates their carrying value based upon current rates available to the Company.
Fair Value Measurements	Fair Value Measurements The Company records certain financial instruments at fair value, including: cash equivalents, short term investments and investments. The Company may make an irrevocable election to measure other financial instruments at fair value on an instrument-by-instrument basis; although as of December 31, 2015, the Company has not chosen to make any such elections. Fair value financial instruments are recorded in accordance with the fair value measurement framework. The Company also measures certain non-financial assets at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets, and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group, and accounting for business combinations. The Company uses the fair value measurement framework to value these assets and reports these fair values in the periods in which they are recorded or written down. The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels. These levels from highest to lowest priority are as follows: • Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities; • Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data. • Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available. The determination of fair value and the assessment of a measurement’s placement within the hierarchy require judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. The Company may also engage external advisors to assist it in determining fair value, as appropriate. Although the Company believes that the recorded fair value of its financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs"). In May 2014, the Financial Accounting Standards Board issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company is currently assessing the impact the adoption of ASU 2014-09 will have on its consolidated financial statements. In November 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company has adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify reporting with the release of the valuation allowance as disclosed in Note 13. Prior periods were not retrospectively adjusted. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements. All other ASUs issued and not yet effective for the year ended December 31, 2015, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory	Inventories consisted of the following items as of December 31, 2015 and 2014 (in thousands): December 31, 2015 2014 Raw materials $ 602 $ 255 Work in process 3,850 3,419 Finished goods 3,405 1,986 Inventory, gross 7,857 5,660 Reserve for obsolescence (397 ) (527 ) Inventory, net $ 7,460 $ 5,133

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and equipment	Property and equipment consist of the following as of December 31, 2015 and 2014 (in thousands): December 31, 2015 2014 Leasehold improvements $ 2,684 $ 2,559 Lab and clean room equipment 4,564 3,040 Furniture and equipment 4,577 2,398 Construction in Progress 2,629 949 Property and equipment, gross 14,454 8,946 Less accumulated depreciation (4,979 ) (3,499 ) Property and equipment, net $ 9,475 $ 5,447

Intangible Assets and Royalty30

Intangible Assets and Royalty Agreement (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets activity summary	Intangible assets are summarized as follows (in thousands): December 31, 2015 2014 Weighted Cost Cost Licenses (a) (b) 10 years $ 1,009 $ 1,009 Patents & Know How (b) 17 years 8,001 7,891 Customer & Supplier Relationships (b) 14 years 3,761 3,761 Tradenames & Trademarks (b) indefinite 1,008 1,008 In Process Research & Development (b) n/a 25 25 Patents in Process (c) n/a 1,823 1,082 Total 15,627 14,776 Less Accumulated amortization (4,864 ) (3,931 ) Net $ 10,763 $ 10,845 (a) On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000 . Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2015, this license had a remaining net book value of approximately $110,000 . (b) On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000 , Patents & Know-How of $7,690,000 , Licenses of $13,000 , Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000 . During 2015 approximately $110,000 of additional costs associated with patents granted during the year were capitalized and included in Patents & Know- How subject to amortization. (c) Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
Estimated future amortization expense of intangible assets	Expected future amortization of intangible assets as of December 31, 2015, is as follows (in thousands): Estimated Amortization Year ending December 31, Expense 2016 $ 936 2017 846 2018 836 2019 836 2020 836 Thereafter 5,465 $ 9,755

Net Income (loss) Per Share (Ta

Net Income (loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Computation of basic and diluted net loss per share	The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except per share data): Year Ended December 31, 2015 2014 2013 Net income (loss) $ 29,446 $ 6,220 $ (4,112 ) Denominator for basic earnings per share - weighted average shares 105,929,205 105,793,008 96,285,504 Effect of dilutive securities: Stock options, warrants, and restricted stock (a) 7,699,277 7,502,496 — Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities 113,628,482 113,295,504 96,285,504 Income (loss) per common share - basic 0.28 0.06 (0.04 ) Income (loss) per common share - diluted $ 0.26 $ 0.05 $ (0.04 ) (a) Securities that are included in the computation of the denominator above, utilizing the treasury stock method for the years ended December 31, 2015 and 2014 are as follows:
Summary of antidilutive securities	Securities that are included in the computation of the denominator above, utilizing the treasury stock method for the years ended December 31, 2015 and 2014 are as follows: Effect of dilutive securities: 2015 2014 Stock Options 7,121,774 7,035,728 Warrants 33,676 226,926 Restricted Stock Awards 543,827 239,842 7,699,277 7,502,496

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock options activity	Activity with respect to the stock options is summarized as follows: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Outstanding at January 1, 2015 16,474,227 $ 3.43 Granted 75,100 $ 9.66 Exercised (2,220,881 ) $ 2.08 Unvested options forfeited (239,322 ) $ 6.66 Vested options expired (69,495 ) $ 2.61 Outstanding at December 31, 2015 14,019,629 $ 3.62 6.5 $ 80,740,577 Vested at December 31, 2015 10,951,694 $ 2.80 6.2 $ 71,955,234 Vested or expected to vest at December 31, 2015 (a) 13,917,122 $ 3.60 6.5 $ 80,496,150 (a) Includes forfeiture adjusted unvested shares.
Summary of stock options outstanding and exercisable	Following is a summary of stock options outstanding and exercisable at December 31, 2015: Options Outstanding Options Exercisable Range of Exercise Prices Number outstanding Weighted- Average Remaining Contractual Term (in years) Weighted- Average Exercise Price Number Exercisable Weighted- Average Exercise Price $0.50 - $0.76 441,429 3.4 $ 0.72 441,429 $ 0.72 $0.87 - $1.35 4,783,304 5.7 1.19 4,783,304 1.19 $1.40 - $2.45 1,641,928 5.1 1.93 1,641,928 1.93 $2.66 - $3.99 957,454 6.8 3.05 907,452 3.00 $4.19 - $6.38 3,552,323 7.4 5.35 2,229,386 5.32 $6.45- $9.78 2,527,525 8.1 7.29 914,703 7.18 $9.90 - $10.99 115,666 8.9 10.43 33,492 10.50 14,019,629 6.5 $ 3.62 10,951,694 $ 2.80
Unvested stock options roll forward	A summary of the status of the Company’s unvested stock options as of December 31, 2015 is presented below: Unvested Stock Options Number of Weighted- Unvested at January 1, 2015 7,193,577 $ 3.08 Granted 75,100 $ 5.15 Cancelled (239,322 ) $ 3.79 Vested (3,961,420 ) $ 2.53 Unvested at December 31, 2015 3,067,935 $ 3.81
Fair value of options valuation assumptions	The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table: Year ended December 31, 2015 2014 2013 Expected volatility 54.35 - 58.14% 58.14 - 64.50% 61.41 - 64.77% Expected life (in years) 6 6 6 Expected dividend yield — — — Risk-free interest rate 1.51 - 1.68% 1.64 - 1.96% 0.85 - 1.88%
Restricted stock awards roll forward	Following is summary information for restricted stock awards for the year ended December 31, 2015. Shares vest over a one to three year period. As of December 31, 2015, there was approximately $16,606,000 of total unrecognized stock-based compensation related to time-based, non-vested restricted stock. That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.1 years . Additionally, during the twelve months ended December 31, 2015, 5,172 shares of common stock valued at approximately $57,000 were issued under the 2006 Plan to a consultant in return for services performed. Number of Weighted-Average Grant Date Unvested at January 1, 2015 1,228,898 $ 7.16 Granted 1,974,259 $ 9.80 Vested (517,883 ) $ 6.90 Forfeited (72,007 ) $ 9.77 Unvested at December 31, 2015 2,613,267 $ 9.14
Allocation of share-based compensation	For the years ended December 31, 2015, 2014, and 2013 the Company recognized stock-based compensation as follows (in thousands): Year Ended December 31, 2015 2014 2013 Cost of sales $ 352 $ 322 $ 279 Research and development 790 660 417 Selling, general and administrative 15,754 10,471 5,314 $ 16,896 $ 11,453 $ 6,010

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Deferred tax assets and liabilities	Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands): December 31, 2015 2014 Deferred tax assets and liabilities: Accruals and prepaids $ 4,606 $ 3,563 Intangible assets 146 619 Property and equipment (1,396 ) (770 ) R&D and other tax credits 3,293 2,086 Stock compensation 7,063 4,163 Charitable contributions — 1 Federal and state basis difference 145 114 Net operating loss 1,763 6,382 Net deferred tax assets $ 15,620 $ 16,158 Valuation allowance (782 ) (16,158 ) $ 14,838 $ —
Reconciliation of the Federal statutory income tax	The reconciliation of the Federal statutory income tax rate of 34% to the effective rate is as follows: December 31, 2015 2014 Federal statutory rate 34.00 % 34.00 % State taxes, net of federal benefit 3.33 % 9.58 % Non deductible compensation 0.63 % 5.59 % Meals & entertainment 2.27 % 5.55 % Stock based compensation - ISO 6.39 % 21.73 % Other (4.58 )% (5.92 )% Valuation allowance (63.33 )% (58.73 )% (21.29 )% 11.80 %
Schedule of current and deferred income tax expense (benefit)	Current and deferred income tax expense (benefit) is as follows (in thousands): December 31, 2015 December 31, 2014 Current: Federal $ 8,452 $ — State 1,218 832 Total current 9,670 832 Deferred: Federal (13,070 ) — State (1,768 ) — Total deferred (14,838 ) — Total expense $ (5,168 ) $ 832
Reconciliation of unrecognized tax benefits	The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in thousands): December 31, 2015 December 31, 2014 Unrecognized tax benefits - January 1 $ — $ — Gross increases - tax positions in current period 170 — Unrecognized tax benefits - December 31 $ 170 $ —

Supplemental Disclosure of Ca34

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Tables)	12 Months Ended
	Dec. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental disclosure of cash flow and non-cash investing and financing activities	Selected cash payments, receipts, and noncash activities are as follows (in thousands) : Years Ended December 31, 2015 2014 2013 Cash paid for interest $ 86 $ 48 $ 36 Income taxes paid 2,293 384 61 Purchases of equipment financed through capital leases — — 355 Retirement of fixed assets 319 — — Deferred financing costs 504 — 27 APIC related tax adjustments 7,757 — — Stock issuance in connection with Earn-Out Liability of 1,174,915 shares — — 5,792 Stock issuance in exchange for convertible debt of 5,272,004 shares — — 5,272 Stock issuance of 16,493 and 15,958 shares in exchange for services performed in 2015 and 2014, respectively 164 117 — Tenant improvement incentive — — 997 Legal fees paid for public offering — — 102 Legal fees related to public offering included in accounts payable — — 30 Legal fees related to public offering included in accrued expenses — — 62

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Estimated annual lease, royalty, and employment agreement expenses	The estimated annual payments are as follows (in thousands): Year ended December 31, 2016 $ 2,818 2017 2,340 2018 1,766 2019 1,763 2020 352 $ 9,039

Quarterly Financial Data (Una36

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Schedule of quarterly financial information	First Quarter Second Quarter Third Quarter Fourth Quarter NET SALES 2015 $ 40,767 $ 45,679 $ 49,015 $ 51,835 2014 19,559 25,573 33,518 39,573 2013 11,556 13,515 16,116 17,994 GROSS MARGIN 2015 $ 35,619 $ 40,590 $ 44,036 $ 46,849 2014 16,582 22,833 30,170 35,973 2013 9,651 11,316 14,002 14,883 NET INCOME (LOSS) 2015 $ 4,087 $ 5,430 $ 6,551 $ 13,378 2014 (922 ) (390 ) 3,700 3,832 2013 (1,620 ) (757 ) (307 ) (1,427 ) NET INCOME (LOSS) 2015 $ 0.04 $ 0.05 $ 0.06 $ 0.13 2014 (0.01 ) — 0.03 0.04 2013 (0.02 ) (0.01 ) — (0.01 ) NET INCOME (LOSS) 2015 $ 0.04 $ 0.05 $ 0.06 $ 0.11 2014 (0.01 ) — 0.03 0.03 2013 (0.02 ) (0.01 ) — (0.01 )

Nature of Business (Details)

Nature of Business (Details)	12 Months Ended
	Dec. 31, 2015Business_Segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of business segments	1

Significant Accounting Polici38

Significant Accounting Policies (Details)	3 Months Ended	12 Months Ended
	Dec. 31, 2013USD ($)	Dec. 31, 2015USD ($)Business_Segmentdistributor	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2012USD ($)	Jul. 31, 2010USD ($)
Market Concentrations and Credit Risk [Line Items]
Number of business segments | Business_Segment		1
FDIC insured amount						$ 250,000
Cash and cash equivalents uninsured amount		$ 27,700,000	$ 44,600,000
Number of major customers | distributor		1
Impairment of intangible assets				$ 368,000	$ 1,800,000
Impairment of Long-lived Assets [Abstract]
Impairment loss	$ 30,000
Grant Income [Abstract]
Proceeds from grant				250,000
Patents
Impairment of Long-lived Assets [Abstract]
Intangible assets, net of accumulated amortization		$ 851,000	$ 594,000	$ 689,000
Minimum
Property and Equipment [Abstract]
Property and equipment estimated useful life		3 years
Maximum
Property and Equipment [Abstract]
Property and equipment estimated useful life		7 years
Revenue | AvKare
Market Concentrations and Credit Risk [Line Items]
Concentration of risk (percent)		24.00%	34.00%	56.00%
Accounts Receivable | AvKare
Market Concentrations and Credit Risk [Line Items]
Concentration of risk (percent)		26.00%	33.00%

Liquidity and Capital Resourc39

Liquidity and Capital Resources (Details) - USD ($)	Oct. 12, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument [Line Items]
Cash and cash equivalents		$ 28,486,000	$ 46,582,000	$ 44,078,000	$ 6,754,000
Total current assets		96,310,000	85,677,000
Total current liabilities		26,777,000	18,404,000
Net working capital		69,533,000
Net cash flows from operating activities		$ 18,807,000	$ 16,802,000	$ (284,000)
Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Debt term	3 years
Senior secured revolving credit facility	$ 50,000,000

Cash Equivalents and Short Te40

Cash Equivalents and Short Term Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 28,486	$ 46,582	$ 44,078	$ 6,754
Short term investments	3,000	5,750
Certificates of Deposit
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents		1,250
Short term investments	$ 3,000	$ 5,750

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 602	$ 255
Work in process	3,850	3,419
Finished goods	3,405	1,986
Inventory, gross	7,857	5,660
Reserve for obsolescence	(397)	(527)
Inventory, net	$ 7,460	$ 5,133

Investments (Details)

Investments (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Investment [Line Items]
Investments	$ 0	$ 3,250,000
Certificates of Deposit
Investment [Line Items]
Investments	$ 0	$ 3,250,000

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property and equipment [Line Items]
Property and equipment, gross	$ 14,454	$ 8,946
Less accumulated depreciation	(4,979)	(3,499)
Property and equipment, net	9,475	5,447
Other liabilities	1,148	1,526
Depreciation expense	1,799	1,197	$ 637
Leasehold improvements
Property and equipment [Line Items]
Property and equipment, gross	2,684	2,559
Lab and clean room equipment
Property and equipment [Line Items]
Property and equipment, gross	4,564	3,040
Furniture and equipment
Property and equipment [Line Items]
Property and equipment, gross	4,577	2,398
Construction in Progress
Property and equipment [Line Items]
Property and equipment, gross	2,629	$ 949
Capital leases
Property and equipment [Line Items]
Property and equipment, net	427
Other liabilities	133
Leasehold improvements paid for by landlord
Property and equipment [Line Items]
Property and equipment, net	$ 1,000

Intangible Assets and Royalty44

Intangible Assets and Royalty Agreement Intangible Asssets Activity Summary (Details) - USD ($)		Jan. 29, 2007	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jan. 05, 2011
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross carrying value			$ 15,627,000	$ 14,776,000
Less Accumulated amortization			(4,864,000)	(3,931,000)
Intangible Assets, Net			10,763,000	10,845,000
Net book value			9,755,000
Amortization of intangible assets			933,000	928,000	$ 1,054,000
Tradenames & Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived			1,008,000	1,008,000
Tradenames & Trademarks | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived						$ 1,008,000
In Process Research & Development
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived			25,000	25,000
In Process Research & Development | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived						25,000
Patents in Process
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived			$ 1,823,000	1,082,000
Licenses
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Lives	[1],[2],[3]		10 years
Gross carrying value	[1],[2],[3]		$ 1,009,000	1,009,000
Licenses | Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.
Finite-Lived Intangible Assets [Line Items]
Acquisition price		$ 996,000
Maximum time of approval		30 days
Contingent payments to licensor			$ 200,000
Contingent royalty to be paid to licensor			3.00%
Annual royalty payment		$ 50,000
Net book value			$ 110,000
Licenses | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value	[1],[2],[3]					13,000
Patents & Know How
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Lives			17 years
Gross carrying value			$ 8,001,000	7,891,000
Patents & Know How | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value						7,690,000
Finite-lived intangible assets, costs			$ 110,000
Customer & Supplier Relationships
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Lives			14 years
Gross carrying value			$ 3,761,000	$ 3,761,000
Customer & Supplier Relationships | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value						$ 3,761,000
[1]	Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
[2]	On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2015, this license had a remaining net book value of approximately $110,000.
[3]	On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. During 2015 approximately $110,000 of additional costs associated with patents granted during the year were capitalized and included in Patents & Know- How subject to amortization.

Intangible Assets and Royalty45

Intangible Assets and Royalty Agreement Expected Future Amortization of Intangible Assets (Details) $ in Thousands	Dec. 31, 2015USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2,016	$ 936
2,017	846
2,018	836
2,019	836
2,020	836
Thereafter	5,465
Net book value	$ 9,755

Long-Term Debt (Details)

Long-Term Debt (Details) - USD ($)	Oct. 12, 2015	Dec. 31, 2011	Feb. 28, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Placement fee, warrants issued (in shares)				16,493	15,958
Amortization of debt discount				$ 0	$ 0	$ 1,328,000
5% Convertible Senior Secured Promissory Note
Debt Instrument [Line Items]
Annual interest rate		5.00%				5.00%
Proceeds from issuance of debt		$ 5,000,000
Principal of notes convertible (in shares)		5,000,000
Accrued but unpaid interest (in dollars per share)		$ 1
Placement fee		$ 32,800
Placement fee, warrants issued (in shares)		42,400
Warrant exercise price (in dollars per share)		$ 1.09
Fair value of placement fee warrants		$ 15,000
Direct costs of sale of notes		47,800
5% Convertible Senior Secured Promissory Note | Chairman and CEO
Debt Instrument [Line Items]
Proceeds from issuance of debt		$ 500,000
Loan Agreement
Debt Instrument [Line Items]
Total amount of debt plus accrued interest			$ 5,272,000
Convertible secured promissory note to common stock (in shares)			5,272,000
Amortization of debt discount						$ 1,328,000
Loan Agreement | Chief Executive Officer
Debt Instrument [Line Items]
Convertible secured promissory note to common stock (in shares)			532,260
Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Direct costs of sale of notes	$ 500,000
Maximum borrowing capacity	50,000,000
Uncommitted incremental facility	$ 35,000,000
Debt term	3 years
Credit Agreement | Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	1.50%
Credit Agreement | Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	2.25%

Net Income (loss) Per Share Com

Net Income (loss) Per Share Computation of Basic and Dilutive Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Net income (loss)	$ 13,378	$ 6,551	$ 5,430	$ 4,087	$ 3,832	$ 3,700	$ (390)	$ (922)	$ (1,427)	$ (307)	$ (757)	$ (1,620)	$ 29,446	$ 6,220	$ (4,112)
Denominator for basic earnings per share - weighted average shares (in shares)													105,929,205	105,793,008	96,285,504
Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (in shares)													7,699,277	7,502,496	0
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities (in shares)													113,628,482	113,295,504	96,285,504
Income (loss) per common share - basic (in dollars per share)	$ 0.13	$ 0.06	$ 0.05	$ 0.04	$ 0.04	$ 0.03	$ 0	$ (0.01)	$ (0.01)	$ 0	$ (0.01)	$ (0.02)	$ 0.28	$ 0.06	$ (0.04)
Income (loss) per common share - diluted (in dollars per share)	$ 0.11	$ 0.06	$ 0.05	$ 0.04	$ 0.03	$ 0.03	$ 0	$ (0.01)	$ (0.01)	$ 0	$ (0.01)	$ (0.02)	$ 0.26	$ 0.05	$ (0.04)

Net Income (loss) Per Share Sum

Net Income (loss) Per Share Summary of Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,699,277	7,502,496
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,121,774	7,035,728
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	33,676	226,926
Restricted Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	543,827	239,842

Common Stock Placements (Detail

Common Stock Placements (Details) - Common Stock $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Dec. 31, 2013USD ($)$ / sharesshares	Dec. 31, 2013$ / sharesshares
Sale of stocks and warrants [Line Items]
Shares issued (in shares) | shares	5,750,000	5,750,000
Share issue price (in dollars per share) | $ / shares	$ 6.80	$ 6.80
Proceeds from shares issued	$ 36,704
Legal fees paid for secondary offering	$ 194

Equity Narrative (Details)

Equity Narrative (Details)	12 Months Ended
	Dec. 31, 2015USD ($)plan$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / shares	Nov. 18, 2015$ / sharesshares	May 12, 2014USD ($)
Class of Stock [Line Items]
Number of share-based compensation plans | plan	3
Outstanding assumed options (in shares) | shares	70,000
Number of shares available to be issued (in shares) | shares	26,500,000
Intrinsic value of options exercised	$ 17,181,000	$ 10,566,000	$ 8,864,000
Intrinsic value of options vested	10,044,000	$ 6,615,000	$ 3,351,000
Total unrecognized compensation expense	$ 6,241,000
Weighted-average grant date fair value for options granted during the period (in dollars per share) | $ / shares	$ 5.15	$ 4.18	$ 3.08
Shares issued for services performed (in shares) | shares	16,493	15,958
Stock issuance of 16,493 and 15,958 shares in exchange for services performed in 2015 and 2014, respectively	$ 164,000	$ 117,000	$ 0
Warrants, term	5 years
Authorized share amount for repurchase	$ 60,000,000	$ 20,000,000			$ 10,000,000
Stock repurchase (in shares) | shares	4,610,000
Shares repurchased, value	$ 40,143,000
Commissions	136,000
Remaining authorizations under the repurchase program, amount	$ 14,274,000
Common Stock
Class of Stock [Line Items]
Shares issued for services performed (in shares) | shares	11,321	15,958
Consultant | Common Stock
Class of Stock [Line Items]
Shares issued for services performed (in shares) | shares	5,172
Stock issuance of 16,493 and 15,958 shares in exchange for services performed in 2015 and 2014, respectively	$ 57,000
Restricted Stock
Class of Stock [Line Items]
Total unrecognized stock-based compensation related to time-based, nonvested restricted stock	$ 16,606,000
Expenses expected to be recognized over a weighted-average period	2 years 1 month 6 days
Minimum | Restricted Stock
Class of Stock [Line Items]
Vesting period	1 year
Maximum | Restricted Stock
Class of Stock [Line Items]
Vesting period	3 years
Warrants
Class of Stock [Line Items]
Warrants outstanding (in shares) | shares				42,400
Warrants outstanding (in dollars per share) | $ / shares				$ 1.09

Equity Activity of Stock Option

Equity Activity of Stock Options (Details)	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Number of Shares
Outstanding, beginning of period (in shares) | shares	16,474,227
Granted (in shares) | shares	75,100
Exercised (in shares) | shares	(2,220,881)
Unvested options forfeited (in shares) | shares	(239,322)
Vested options expired (in shares) | shares	(69,495)
Outstanding, end of period (in shares) | shares	14,019,629
Vested at end of period (in shares) | shares	10,951,694
Exercisable options, vested and expected to vest (in shares) | shares	13,917,122	[1]
Weighted- Average Exercise Price
Outstanding, weighted average exercise price, beginning of period (in dollars per share) | $ / shares	$ 3.43
Granted, weighted average exercise price (in dollars per share) | $ / shares	9.66
Exercised, weighted average exercise price (in dollars per share) | $ / shares	2.08
Unvested options forfeited weighted-average exercise price (in dollars per share) | $ / shares	6.66
Vested options expired weighted-average exercise price (in dollars per share) | $ / shares	2.61
Outstanding, weighted average exercise price, end of period (in dollars per share) | $ / shares	3.62
Vested at end of period weighted average exercise price (in dollars per share) | $ / shares	2.80
Vested and expected to vest, weighted average exercise price (in dollars per share) | $ / shares	$ 3.60	[1]
Stock options, additional disclosures
Outstanding options, weighted average remaining contractual term	6 years 6 months
Vested at end of period weighted average remaining contractual term	6 years 2 months 12 days
Vested and expected to vest, weighted average remaining contractual term	6 years 6 months	[1]
Outstanding intrinsic value | $	$ 80,740,577
Vested at end of period aggregate intrinsic value | $	71,955,234
Vested and expected to vest, aggregate intrinsic value | $	$ 80,496,150	[1]
[1]	Includes forfeiture adjusted unvested shares.

Equity Exercise Price Ranges (D

Equity Exercise Price Ranges (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of outstanding options (in shares) | shares	14,019,629
Outstanding options, weighted average remaining contractual term	6 years 6 months
Outstanding options, weighted average exercise price (in dollars per share)	$ 3.62
Number of exercisable options (in shares) | shares	10,951,694
Exercisable options, weighted average exercise price (in dollars per share)	$ 2.80
$0.50 - $0.76
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	0.50
Exercise price range, upper range limit (in dollars per share)	$ 0.76
Number of outstanding options (in shares) | shares	441,429
Outstanding options, weighted average remaining contractual term	3 years 4 months 24 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 0.72
Number of exercisable options (in shares) | shares	441,429
Exercisable options, weighted average exercise price (in dollars per share)	$ 0.72
$0.87 - $1.35
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	0.87
Exercise price range, upper range limit (in dollars per share)	$ 1.35
Number of outstanding options (in shares) | shares	4,783,304
Outstanding options, weighted average remaining contractual term	5 years 8 months 12 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 1.19
Number of exercisable options (in shares) | shares	4,783,304
Exercisable options, weighted average exercise price (in dollars per share)	$ 1.19
$1.40 - $2.45
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	1.40
Exercise price range, upper range limit (in dollars per share)	$ 2.45
Number of outstanding options (in shares) | shares	1,641,928
Outstanding options, weighted average remaining contractual term	5 years 1 month 6 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 1.93
Number of exercisable options (in shares) | shares	1,641,928
Exercisable options, weighted average exercise price (in dollars per share)	$ 1.93
$2.66 - $3.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	2.66
Exercise price range, upper range limit (in dollars per share)	$ 3.99
Number of outstanding options (in shares) | shares	957,454
Outstanding options, weighted average remaining contractual term	6 years 9 months 18 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 3.05
Number of exercisable options (in shares) | shares	907,452
Exercisable options, weighted average exercise price (in dollars per share)	$ 3
$4.19 - $6.38
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	4.19
Exercise price range, upper range limit (in dollars per share)	$ 6.38
Number of outstanding options (in shares) | shares	3,552,323
Outstanding options, weighted average remaining contractual term	7 years 4 months 24 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 5.35
Number of exercisable options (in shares) | shares	2,229,386
Exercisable options, weighted average exercise price (in dollars per share)	$ 5.32
$6.45- $9.78
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	6.45
Exercise price range, upper range limit (in dollars per share)	$ 9.78
Number of outstanding options (in shares) | shares	2,527,525
Outstanding options, weighted average remaining contractual term	8 years 1 month 6 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 7.29
Number of exercisable options (in shares) | shares	914,703
Exercisable options, weighted average exercise price (in dollars per share)	$ 7.18
$9.90 - $10.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	9.90
Exercise price range, upper range limit (in dollars per share)	$ 10.99
Number of outstanding options (in shares) | shares	115,666
Outstanding options, weighted average remaining contractual term	8 years 10 months 24 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 10.43
Number of exercisable options (in shares) | shares	33,492
Exercisable options, weighted average exercise price (in dollars per share)	$ 10.50

Equity Summary of Unvested Stoc

Equity Summary of Unvested Stock Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Number of Shares
Unvested, beginning of period (in shares)	7,193,577
Granted (in shares)	75,100
Cancelled (in shares)	(239,322)
Vested (in shares)	(3,961,420)
Unvested, end of period (in shares)	3,067,935	7,193,577
Weighted- Average Grant Date Fair Value
Unvested, beginning of period (in dollars per share)	$ 3.08
Granted (in dollars per share)	5.15	$ 4.18	$ 3.08
Cancelled (in dollars per share)	3.79
Vested (in dollars per share)	2.53
Unvested, end of period (in dollars per share)	$ 3.81	$ 3.08

Equity Assumptions (Details)

Equity Assumptions (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair value options valuation assumptions [Abstract]
Expected life (in years)	6 years	6 years	6 years
Expected dividend yield, percent	0.00%	0.00%	0.00%
Risk-free interest rate, minimum	1.51%	1.64%	0.85%
Risk-free interest rate, maximum	1.68%	1.96%	1.88%
Minimum
Fair value options valuation assumptions [Abstract]
Expected volatility, percent	54.35%	58.14%	61.41%
Maximum
Fair value options valuation assumptions [Abstract]
Expected volatility, percent	58.14%	64.50%	64.77%

Equity Summary of Restricted St

Equity Summary of Restricted Stock Awards (Details) - Restricted Stock	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Number of Shares
Unvested, beginning of period | shares	1,228,898
Granted | shares	1,974,259
Vested | shares	(517,883)
Forfeited | shares	(72,007)
Unvested, end of period | shares	2,613,267
Weighted- Average Grant Date Fair Value
Unvested, beginning of period (in dollars per share) | $ / shares	$ 7.16
Granted (in dollars per share) | $ / shares	9.80
Vested (in dollars per share) | $ / shares	6.90
Forfeited (in dollars per share) | $ / shares	9.77
Unvested, end of period (in dollars per share) | $ / shares	$ 9.14

Equity Recognized Stock-Based C

Equity Recognized Stock-Based Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation [Abstract]
Stock-based compensation expense	$ 16,896	$ 11,453	$ 6,010
Cost of sales
Share-based Compensation [Abstract]
Stock-based compensation expense	352	322	279
Research and development
Share-based Compensation [Abstract]
Stock-based compensation expense	790	660	417
Selling, general and administrative
Share-based Compensation [Abstract]
Stock-based compensation expense	$ 15,754	$ 10,471	$ 5,314

Income Taxes Deferred Tax Asset

Income Taxes Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets and liabilities [Abstract]
Accruals and prepaids	$ 4,606	$ 3,563
Intangible assets	146	619
Property and equipment	(1,396)	(770)
R&D and other tax credits	3,293	2,086
Stock compensation	7,063	4,163
Charitable contributions	0	1
Federal and state basis difference	145	114
Net operating loss	1,763	6,382
Net deferred tax assets	15,620	16,158
Valuation allowance	(782)	(16,158)
Deferred tax assets and liabilities, net of valuation allowance	$ 14,838	$ 0

Income Taxes Reconciliation of

Income Taxes Reconciliation of the Federal Statutory Income Tax (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Federal statutory rate	34.00%	34.00%
State taxes, net of federal benefit	3.33%	9.58%
Non deductible compensation	0.63%	5.59%
Meals & entertainment	2.27%	5.55%
Stock based compensation - ISO	6.39%	21.73%
Other	(4.58%)	(5.92%)
Valuation allowance	(63.33%)	(58.73%)
Effective income tax rate	(21.29%)	11.80%

Income Taxes Schedule of curren

Income Taxes Schedule of current and deferred income tax expense (benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current:
Federal	$ 8,452	$ 0
State	1,218	832
Total current	9,670	832
Deferred:
Federal	(13,070)	0
State	(1,768)	0
Total deferred	(14,838)	0
Total expense	$ (5,168)	$ 832	$ 100

Income Taxes Reconciliation o60

Income Taxes Reconciliation of unrecognized tax benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Unrecognized tax benefits, beginning of period	$ 0	$ 0
Gross increases - tax positions in current period	170	0
Unrecognized tax benefits, end of period	$ 170	$ 0

Income Taxes Narrative (Details

Income Taxes Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Operating Loss Carryforwards [Line Items]
Federal statutory rate	34.00%	34.00%
Valuation allowance	$ 782,000	$ 16,158,000
Net valuation allowance release	(15,376,000)
Operating loss carry forwards	579,000	27,552,000
Net deferred tax assets	15,620,000	16,158,000
Tax benefit resulted in increase in equity	7,757,000
Stock compensation	1,661,000
Unrecognized tax benefits that would affect effective tax rate	170,000	0
Adjustments to tax accounts	170,000	$ 0
Federal
Operating Loss Carryforwards [Line Items]
Net valuation allowance release	(197,000)
Net deferred tax assets	197,000
State
Operating Loss Carryforwards [Line Items]
Valuation allowance	585,000
Net deferred tax assets	1,566,000
Additional Paid-in
Operating Loss Carryforwards [Line Items]
Tax benefit resulted in increase in equity	$ 7,757,000

Supplemental Disclosure of Ca62

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash and Cash Equivalents [Line Items]
Cash paid for interest	$ 86	$ 48	$ 36
Income taxes paid	2,293	384	61
Purchases of equipment financed through capital leases	0	0	355
Retirement of fixed assets	319	0	0
Deferred financing costs	504	0	27
APIC related tax adjustments	7,757	0	0
Stock issuance in connection with Earn-Out Liability of 1,174,915 shares	0	0	$ 5,792
Stock issued for earn-out liability (in shares)			1,174,915
Stock issuance in exchange for convertible debt of 5,272,004 shares	0	0	$ 5,272
Stock issued for convertible debt (in shares)			5,272,004
Stock issuance of 16,493 and 15,958 shares in exchange for services performed in 2015 and 2014, respectively	$ 164	$ 117	$ 0
Shares issued for services performed (in shares)	16,493	15,958
Tenant improvement incentive	$ 0	$ 0	997
Legal fees paid for public offering	0	0	102
Accounts Payable
Cash and Cash Equivalents [Line Items]
Legal fees paid for public offering	0	0	30
Accrued Expenses
Cash and Cash Equivalents [Line Items]
Legal fees paid for public offering	$ 0	$ 0	$ 62

401k Plan (Details)

401k Plan (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Compensation and Retirement Disclosure [Abstract]
Minimum age require to qualify for pension plan	21 years
Minimum service period require to qualify for pension plan	3 months
Maximum wages deferred, percent	100.00%
Maximum eligible wages deferred by participants per year	$ 18,000
Minimum age for additional contribution beyond normal plan	50 years
Defined benefit plan, contributions by plan participants	$ 6,000
Employer matching contribution, percent	6.00%

Commitments and Contingencies E

Commitments and Contingencies Estimated Annual Lease, Royalty, and Employment Agreement Expenses (Details) $ in Thousands	Dec. 31, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,016	$ 2,818
2,017	2,340
2,018	1,766
2,019	1,763
2,020	352
Total Contractual commitments	$ 9,039

Commitments and Contingencies N

Commitments and Contingencies Narrative (Details) $ in Thousands	1 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2015USD ($)claim	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 30, 2015term	Dec. 22, 2015term	Oct. 02, 2015term	Aug. 18, 2015claim	Jul. 10, 2015claim	Jun. 29, 2015claim
Loss Contingencies [Line Items]
Lessee expiration period (years)		5 years
Rent and operating leases expense | $		$ 1,317	$ 1,130	$ 1,000
Period for plaintiff to proceed with case (days)	120 days
Product Concentration Risk | Sales Revenue, Net
Loss Contingencies [Line Items]
Percentage of revenue (percent)		12.00%
Letters of Credit
Loss Contingencies [Line Items]
Standby letters of credit | $		$ 235
Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims		3
Liventa Action [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of dispute claim terms at issue | term					1	30
Liventa Action, 701 Patent [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims								6
Liventa Action, 437 Patent [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims								7
Opinion allowing a review of patent, number								1
Bone Bank Action [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims									5	7
Number of dispute claim terms at issue | term							1
Opinion allowing a review of patent, number									2

Quarterly Financial Data (Una66

Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
NET SALES	$ 51,835	$ 49,015	$ 45,679	$ 40,767	$ 39,573	$ 33,518	$ 25,573	$ 19,559	$ 17,994	$ 16,116	$ 13,515	$ 11,556	$ 187,296	$ 118,223	$ 59,181
GROSS MARGIN	46,849	44,036	40,590	35,619	35,973	30,170	22,833	16,582	14,883	14,002	11,316	9,651	167,094	105,558	49,853
NET INCOME (LOSS)	$ 13,378	$ 6,551	$ 5,430	$ 4,087	$ 3,832	$ 3,700	$ (390)	$ (922)	$ (1,427)	$ (307)	$ (757)	$ (1,620)	$ 29,446	$ 6,220	$ (4,112)
Net income (loss) per common share - basic (in dollars per share)	$ 0.13	$ 0.06	$ 0.05	$ 0.04	$ 0.04	$ 0.03	$ 0	$ (0.01)	$ (0.01)	$ 0	$ (0.01)	$ (0.02)	$ 0.28	$ 0.06	$ (0.04)
Net income (loss) per common share - diluted (in dollars per share)	$ 0.11	$ 0.06	$ 0.05	$ 0.04	$ 0.03	$ 0.03	$ 0	$ (0.01)	$ (0.01)	$ 0	$ (0.01)	$ (0.02)	$ 0.26	$ 0.05	$ (0.04)

Subsequent Events (Details)

Subsequent Events (Details) - Stability Biologics, LLC [Member] - Subsequent Event $ in Thousands	Jan. 13, 2016USD ($)
Subsequent Event [Line Items]
Consideration transferred for business acquired	$ 10,000
Payments to acquire businesses paid in cash (percent)	60.00%
Payments to acquire businesses paid in shares of common stock (percent)	40.00%
Debt assumed	$ 800
Amount of receivable eliminated	$ 2,400
Contingent consideration earn out arrangement term (in years)	2 years
Earn out to be paid in cash (percent)	60.00%
Earn out to be paid in shares of common stock (percent)	40.00%

Schedule II - Valuation and Q68

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Allowance for doubtful accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 1,750	$ 407	$ 49
Additions charged to Expense or Revenue	1,698	1,357	391
Deductions and write-offs	(178)	(14)	(33)
Balance at End of Year	3,270	1,750	407
Allowance for product returns
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	841	215	89
Additions charged to Expense or Revenue	3,257	2,215	917
Deductions and write-offs	(2,836)	(1,589)	(791)
Balance at End of Year	1,262	841	215
Allowance for obsolescence
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	527	322	159
Additions charged to Expense or Revenue	540	405	213
Deductions and write-offs	(670)	(200)	(50)
Balance at End of Year	$ 397	$ 527	$ 322